The biopharmaceutical companies Novartis AG and Amgen Inc. have signed on as limited partners in a new $265 million venture capital fund raised by the Cambridge firm Atlas Venture.
The new fund, Atlas Venture Fund IX, will invest in biomedical and life sciences start-ups.
Separately, Novartis, a Swiss company that runs its global research operations from Cambridge, and California-based Amgen, which also has a research center in Cambridge, have entered into corporate strategic partnerships with Atlas Venture, the partners said.
The alliances will “provide Amgen and Novartis with strategic proximity to Atlas Venture’s start-up formation activities around innovative, potentially high impact medicines, and catalyze future collaborations around translational research,” the venture firm said in a statement.
Robert WeismanRobert Weisman can be reached at firstname.lastname@example.org. Follow him on Twitter @GlobeRobW.